RS32204A - Čvrsta formulacija leka za derivat piperazinuree - Google Patents

Čvrsta formulacija leka za derivat piperazinuree

Info

Publication number
RS32204A
RS32204A YU32204A YUP32204A RS32204A RS 32204 A RS32204 A RS 32204A YU 32204 A YU32204 A YU 32204A YU P32204 A YUP32204 A YU P32204A RS 32204 A RS32204 A RS 32204A
Authority
RS
Serbia
Prior art keywords
methyl
drug formulation
ureido
phenoxy
carbonyl
Prior art date
Application number
YU32204A
Other languages
English (en)
Serbian (sr)
Inventor
Heiko Kranz
Christoph Volkel
Ralph Lipp
Johannes Tack
Herbert Wiesinger
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of RS32204A publication Critical patent/RS32204A/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
YU32204A 2001-10-18 2002-10-07 Čvrsta formulacija leka za derivat piperazinuree RS32204A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10152351A DE10152351B4 (de) 2001-10-18 2001-10-18 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
PCT/EP2002/011229 WO2003035037A1 (de) 2001-10-18 2002-10-07 Feste arzneimittelformulierung für ein piperazinharnstoffderivat

Publications (1)

Publication Number Publication Date
RS32204A true RS32204A (sr) 2006-10-27

Family

ID=7703496

Family Applications (1)

Application Number Title Priority Date Filing Date
YU32204A RS32204A (sr) 2001-10-18 2002-10-07 Čvrsta formulacija leka za derivat piperazinuree

Country Status (23)

Country Link
EP (1) EP1435917A1 (pl)
JP (1) JP2005506365A (pl)
KR (1) KR20040047920A (pl)
CN (1) CN1571660A (pl)
AR (1) AR037111A1 (pl)
AU (1) AU2002333896B2 (pl)
BR (1) BR0213340A (pl)
CA (1) CA2463951A1 (pl)
CO (1) CO5580740A2 (pl)
DE (1) DE10152351B4 (pl)
EC (1) ECSP045108A (pl)
HR (1) HRP20040435A2 (pl)
IL (1) IL161166A0 (pl)
MX (1) MXPA04003522A (pl)
NO (1) NO20042022L (pl)
NZ (1) NZ532287A (pl)
PE (1) PE20030472A1 (pl)
PL (1) PL367987A1 (pl)
RS (1) RS32204A (pl)
RU (1) RU2311172C2 (pl)
UY (1) UY27500A1 (pl)
WO (1) WO2003035037A1 (pl)
ZA (1) ZA200403781B (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1723196A (zh) 2001-06-27 2006-01-18 史密丝克莱恩比彻姆公司 作为二肽酶抑制剂的氟代吡咯烷
EP1749519A1 (de) 2005-08-05 2007-02-07 Schering Aktiengesellschaft Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
HUE029173T2 (hu) * 2006-04-26 2017-02-28 Alphapharm Pty Ltd Szabályozott hatóanyag-leadású készítmények, amelyek tartalmaznak nem bevont diszkrét egység(ek)et és egy késleltetett hatóanyag-leadású mátrixot
DE102008047910A1 (de) 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
KR101654582B1 (ko) 2016-05-12 2016-09-06 그린로드(주) 원뿔형 부유 고분자 필터, 및 그의 제조장치 및 제조방법, 및 그를 포함하는 수처리 필터
RU2729223C1 (ru) * 2020-05-13 2020-08-05 Мераб Георгиевич Чикобава Дозированная форма для амплификации нуклеиновых кислот

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
FR2668945B1 (fr) * 1990-11-12 1993-02-19 Theramex Nouveau procede de cristallisation des substances organiques et les composes ainsi obtenus.
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
UA57824C2 (uk) * 1998-02-05 2003-07-15 Пфайзер Продактс Інк. Похідні дигідроксигексанової кислоти, фармацевтична композиція, що їх містить (варіанти), та спосіб лікування (варіанти)
ATE400251T1 (de) * 1999-02-09 2008-07-15 Pfizer Prod Inc Zusammensetzungen basischer arzneistoffe mit verbesserter bioverfügbarkeit

Also Published As

Publication number Publication date
NZ532287A (en) 2007-04-27
ZA200403781B (en) 2004-11-29
AU2002333896A2 (en) 2003-05-06
UY27500A1 (es) 2003-06-30
JP2005506365A (ja) 2005-03-03
BR0213340A (pt) 2004-10-05
PE20030472A1 (es) 2003-06-16
KR20040047920A (ko) 2004-06-05
HRP20040435A2 (en) 2005-06-30
WO2003035037A1 (de) 2003-05-01
EP1435917A1 (de) 2004-07-14
CA2463951A1 (en) 2003-05-01
NO20042022L (no) 2004-05-14
IL161166A0 (en) 2004-08-31
MXPA04003522A (es) 2004-07-23
RU2004115328A (ru) 2005-06-10
CN1571660A (zh) 2005-01-26
AU2002333896B2 (en) 2007-07-26
DE10152351B4 (de) 2005-09-22
RU2311172C2 (ru) 2007-11-27
AR037111A1 (es) 2004-10-20
CO5580740A2 (es) 2005-11-30
ECSP045108A (es) 2004-06-28
PL367987A1 (pl) 2005-03-21
DE10152351A1 (de) 2003-05-08

Similar Documents

Publication Publication Date Title
JP6976946B2 (ja) 生理活性の強い、ｕｒａｔ１のインヒビターを含む医薬組成物
EP0173210A2 (de) Pellet-Zubereitung
JPWO2008149894A1 (ja) セルロース系微小核粒子及びその製造方法
CA2858478C (en) Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of manufacturing
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
WO2005117896A1 (de) Formulierungen, die fasudil, eine matrix und einem mantel enthalten
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
RS32204A (sr) Čvrsta formulacija leka za derivat piperazinuree
CA2781826A1 (en) Controlled release pharmaceutical compositions of galantamine
AU2025202455A1 (en) Pharmaceutical composition of darolutamide
JP2017075139A (ja) 低用量薬物を含有する口腔内崩壊錠
ITMI950961A1 (it) Composizioni farmaceutiche contenenti gemfibrozil
US20030087913A1 (en) Solid pharmaceutical agent formulation for a piperazine urea derivative
EP2838518B1 (en) Method of treating acne
EP3184101A1 (en) Levodopa and carbidopa modified release composition
Torrado et al. Tableting of multiparticulate modified release systems
JP2007332074A (ja) 口腔内速崩壊錠およびその製造方法
CN108236609B (zh) 一种gpr40激动剂药物组合物及其制备方法
JP6002870B1 (ja) 低用量薬物を含有する口腔内崩壊錠
AU2006335344A1 (en) Controlled release formulation of divalproic acid and its derivatives
Alany Oral Modified Release Multiple-Unit Particulate Systems: Compressed Pellets, Microparticles and Nanoparticles
US20140309198A1 (en) Method of treating acne